Prudential Financial Inc. Acquires 132,110 Shares of Axovant Sciences Ltd (AXON)

Prudential Financial Inc. increased its position in shares of Axovant Sciences Ltd (NASDAQ:AXON) by 164.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 212,280 shares of the biotechnology company’s stock after acquiring an additional 132,110 shares during the quarter. Prudential Financial Inc. owned approximately 0.20% of Axovant Sciences worth $1,461,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. Lord Abbett & CO. LLC acquired a new position in shares of Axovant Sciences during the 2nd quarter valued at about $696,000. California State Teachers Retirement System boosted its position in shares of Axovant Sciences by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 52,949 shares of the biotechnology company’s stock valued at $1,228,000 after acquiring an additional 4,800 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Axovant Sciences by 16.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock valued at $519,000 after acquiring an additional 3,184 shares during the last quarter. State Street Corp boosted its position in shares of Axovant Sciences by 52.8% during the 2nd quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after acquiring an additional 188,945 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Axovant Sciences during the 2nd quarter valued at about $47,854,000. 96.93% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Axovant Sciences Ltd (NASDAQ:AXON) traded down $0.03 during trading hours on Friday, reaching $5.27. 1,247,240 shares of the company’s stock were exchanged, compared to its average volume of 1,082,181. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. The stock has a market capitalization of $570.86, a price-to-earnings ratio of -2.29 and a beta of 0.06. Axovant Sciences Ltd has a one year low of $4.60 and a one year high of $27.98.

Several research analysts have recently weighed in on the stock. Jefferies Group cut shares of Axovant Sciences from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research report on Thursday, December 21st. BidaskClub cut shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Axovant Sciences in a research report on Friday, December 1st. Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 12th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating on shares of Axovant Sciences in a research report on Friday, November 10th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. Axovant Sciences currently has an average rating of “Hold” and an average target price of $14.18.

COPYRIGHT VIOLATION WARNING: “Prudential Financial Inc. Acquires 132,110 Shares of Axovant Sciences Ltd (AXON)” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/30/axovant-sciences-ltd-axon-stake-lifted-by-prudential-financial-inc.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Institutional Ownership by Quarter for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply